Experimental Hematology
Volume 34, Issue 10 , Pages 1296-1302 , October 2006

Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma

  • Roland Fenk

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • Corresponding Author InformationOffprint requests to: Roland Fenk, M.D. Dept. of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University of Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
    • ,
  • Nadine Hieronimus

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • ,
  • Ulrich Steidl

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • Harvard Institutes of Medicine, Hematology/Oncology Division, Boston, Mass., USA
    • ,
  • Ingmar Bruns

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • ,
  • Thorsten Graef

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • ,
  • Fabian Zohren

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • ,
  • Leilani Ruf

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • ,
  • Rainer Haas

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
    • ,
  • Guido Kobbe

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany

Received 24 April 2006 ,Revised 26 May 2006 ,Accepted 5 June 2006.

References 

  1. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883
  2. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am. 1997;11:133–146
  3. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–2502
  4. Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol. 2005;130:588–594
  5. Qazilbash MH, Saliba R, de Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006;106:1084–1089
  6. Krivanova A, Hajek R, Krejci M, et al. Second autologous transplantation for multiple myeloma patients relapsing after the first autograft—a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group. Onkologie. 2004;27:275–279
  7. Haas R, Gericke G, Witt B, Cayeux S, Hunstein W. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol. 1993;21:109–113
  8. Valteau-Couanet D, Faucher C, Auperin A, et al. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant. 2005;36:547–552
  9. Olivieri A, Scortechini I, Capelli D, et al. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant. 2004;34:693–702
  10. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–731
  11. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522–2528
  12. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2005;35:889–893
  13. Jagasia MH, Greer JP, Morgan DS, et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant. 2005;35:1165–1169
  14. Vanstraelen G, Frere P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol. 2006;34:382–388
  15. Morris TC, Magill MK, Drake M, et al. The endogenous granulocyte colony-stimulating factor response following autologous peripheral blood stem cell transplantation is impaired in patients with myeloma. Br J Haematol. 2002;117:646–649
  16. Steidl U, Fenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant. 2005;35:33–36
  17. Kündgen R, Fenk R, Bruns I, et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;38:69–70
  18. Piccirillo N, Sica S, Laurenti L, et al. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1999;23:1245–1250
  19. Farese AM, Yang BB, Roskos L, Stead RB, MacVittie TJ. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant. 2003;32:399–404
  20. Bence-Bruckler I, Bredeson C, Atkins H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant. 1998;22:965–969
  21. Bolwell BJ, Pohlman B, Andresen S, et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 1998;21:369–373
  22. Straka C, Oduncu F, Hinke A, et al. Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients. Blood. 2004;104:1989–1994

PII: S0301-472X(06)00377-8

doi: 10.1016/j.exphem.2006.06.002

Experimental Hematology
Volume 34, Issue 10 , Pages 1296-1302 , October 2006

Article Tools

* Image Usage & Resolution